The impact of chemotherapy on frontal lobe executive functioning in adolescents and young adults diagnosed and treated for blood cancers: a systematic review
- 1Great Ormond Street UCL Institute of Child Health, London, UK
- 2Guy’s and St Thomas’ NHS Foundation Trust, London, UK
- 3Peninsula Medical School, University of Plymouth, Plymouth, UK
Abstract
Background: Cancer-related cognitive impairment (CRCI), often termed “chemobrain,” is a recognised effect of cancer therapy. However, most research has focused on older adults with solid tumours, leaving the neurocognitive consequences of chemotherapy in adolescents and young adults (AYAs) with blood cancers poorly understood. Because executive functions (EF)—including working memory, inhibition, flexibility, planning, and processing speed—continue to mature into early adulthood, this group may be particularly vulnerable to neurotoxicity.
Methods: Following PRISMA 2020 guidelines, a systematic search was conducted in PubMed, PsycINFO, Embase (including Embase Classic), MEDLINE, and Scopus. Eligible studies included participants aged 16–25 years at diagnosis of a haematological malignancy who had received chemotherapy and were assessed for EF outcomes using validated measures. Methodological quality was appraised with an adapted Newcastle–Ottawa Scale (NOS).
Results: Twelve studies met inclusion criteria. Evidence indicated consistent vulnerability in working memory and processing speed, with less consistent findings for inhibition, flexibility, and planning. Heterogeneous methods, small samples, and frequent reliance on self-report limited comparability. High-quality, controlled studies employing objective tests reported measurable EF deficits following chemotherapy.
Conclusions: Chemotherapy may compromise EF in AYAs with blood cancers, though the evidence base remains methodologically limited. Standardised EF assessment, longitudinal research with baseline data, and integration of cognitive monitoring into survivorship care are recommended.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12885-026-16731-7.
Related
- Executive functioning and binge-watching behaviors in adolescents: a network analysis
- Profiles of everyday executive functioning in relation to adaptive behaviour in children and adolescents with Down syndrome
- The effects of physical exercise on executive function, internalizing symptoms and externalizing symptoms in children and adolescents with attention-deficit/hyperactivity disorder: a systematic review and meta-analysis.
- Effects of exercise interventions on executive function in adolescents: a systematic review and three-level meta-analysis of randomized controlled trials
- Interoception-Based Interventions for Executive Functioning and Behavioral Outcomes in Children and Young Adults: A Scoping Review
BibTeX
@article{patwardhan2026impact,
title = {{The impact of chemotherapy on frontal lobe executive functioning in adolescents and young adults diagnosed and treated for blood cancers: a systematic review}},
author = {Raina Patwardhan and Clare Jacobson and Jaishibani Mande Nagarajan and Lee D Hudson},
journal = {BMC Cancer},
year = {2026},
month = aug,
doi = {10.1186/s12885-026-16731-7},
url = {https://doi.org/10.1186/s12885-026-16731-7},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The impact of chemotherapy on frontal lobe executive functioning in adolescents and young adults diagnosed and treated for blood cancers: a systematic review
AU - Raina Patwardhan
AU - Clare Jacobson
AU - Jaishibani Mande Nagarajan
AU - Lee D Hudson
PY - 2026
DA - 2026/08/15
JO - BMC Cancer
DO - 10.1186/s12885-026-16731-7
UR - https://doi.org/10.1186/s12885-026-16731-7
AB - Background: Cancer-related cognitive impairment (CRCI), often termed “chemobrain,” is a recognised effect of cancer therapy. However, most research has focused on older adults with solid tumours, leaving the neurocognitive consequences of chemotherapy in adolescents and young adults (AYAs) with blood cancers poorly understood. Because executive functions (EF)—including working memory, inhibition, flexibility, planning, and processing speed—continue to mature into early adulthood, this group may be particularly vulnerable to neurotoxicity. Methods: Following PRISMA 2020 guidelines, a systematic search was conducted in PubMed, PsycINFO, Embase (including Embase Classic), MEDLINE, and Scopus. Eligible studies included participants aged 16–25 years at diagnosis of a haematological malignancy who had received chemotherapy and were assessed for EF outcomes using validated measures. Methodological quality was appraised with an adapted Newcastle–Ottawa Scale (NOS). Results: Twelve studies met inclusion criteria. Evidence indicated consistent vulnerability in working memory and processing speed, with less consistent findings for inhibition, flexibility, and planning. Heterogeneous methods, small samples, and frequent reliance on self-report limited comparability. High-quality, controlled studies employing objective tests reported measurable EF deficits following chemotherapy. Conclusions: Chemotherapy may compromise EF in AYAs with blood cancers, though the evidence base remains methodologically limited. Standardised EF assessment, longitudinal research with baseline data, and integration of cognitive monitoring into survivorship care are recommended. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12885-026-16731-7.
SN - 1471-2407
ER -